Clinical trial
Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control
Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control
ClinicalTrials.gov ID: NCT02483936
Sponsor: EMS
Information provided by: EMS (Responsible Party)
Last Update Posted: 2022-08-05
Brief Summary:
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.
Official Title:
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan Medoxomil + Chlorthalidone (40mg + 12.5mg and 40mg + 25mg) Compared With BENICAR HCT® in Hypertension Control
Intervention / Treatment:
- Drug: Olmesartan medoxomil 40mg + chlorthalidone 12,5mg
- Drug: Olmesartan medoxomil 40mg + chlorthalidone 25mg
- Drug: Olmesartan 40mg + Hydrochlorothiazide 12,5mg
- Drug: Olmesartan 40mg + Hydrochlorothiazide 25mg
| Category | Value |
|---|---|
| Study Start (Estimated) | 2023-04 |
| Primary Completion (Estimated) | 2024-06 |
| Study Completion (Estimated) | 2024-09 |
| Enrollment (Estimated) | 348 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers |
OLCEMS0215 |